Crossmark

Novel Therapeutic Options in Treatment of Idiopathic Inflammatory Myopathies

Crossref DOI link: https://doi.org/10.1007/s11940-018-0521-6

Published Online: 2018-07-23

Published Print: 2018-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Goyal, Namita A.

Mozaffar, Tahseen
License Information

Text and Data Mining valid from 2018-07-23
More Information

Article History

First Online: 23 July 2018

Compliance with Ethical Standards

:

: Namita A. Goyal has received grants from Octapharma, GSK, Novartis, Idera, Orphazyme, and BMS.Tahseen Mozaffar has received grants from GSK, Novartis, Idera, Orphazyme, and BMS.

: This article does not contain any studies with human or animal subjects performed by any of the authors.